Alvotech (ALVO)

Sep 25, 2026

Alvotech (NASDAQ:ALVO) shares increased by 3.5% on Thursday, closing at $6.0130, despite an 85% drop in trading volume compared to its average session. The biopharmaceutical company reported quarterly revenue of $106 million, surpassing estimates, but missed earnings expectations with an adjusted loss of $0.11 per share. Analysts generally have a "Moderate Buy" rating for Alvotech, with a consensus price target of $8.50.

Sep 20, 2026

Alvotech (ALVO) shares experienced a 7% increase in afternoon trading on Wednesday following a double upgrade from Barclays. The article, originating from MT Newswires, provides this brief market update. Further details are restricted to premium subscribers of Yahoo Finance Gold or Silver plans.

Sep 19, 2026

Alvotech (NASDAQ:ALVO) shares recently surged by 7.2% to $5.7250, reaching a market capitalization of $1.80 billion. Despite exceeding revenue expectations with $106 million in its latest quarter, the biopharmaceutical company remains unprofitable, reporting a net margin of -36.31%. Analysts currently hold a "Moderate Buy" consensus rating for Alvotech, with an average price target of $8.50, though some firms have downgraded their ratings.

Sep 16, 2026

Alvotech (NASDAQ:ALVO) shares rose 5.6% after Barclays upgraded its rating from Underweight to Overweight and doubled its price target from $4.00 to $8.00. The upgrade was driven by a positive outcome from a US FDA inspection at Alvotech's manufacturing facility, which led to a Voluntary Action Indicated (VAI) classification. This development has cleared the path for the resubmission of several biosimilar applications, with regulatory decisions expected in late 2026 and early 2027.

Sep 16, 2026

Barclays upgraded Alvotech (NASDAQ: ALVO) after the U.S. FDA issued a Voluntary Action Indicated (VAI) classification for its manufacturing facility in Iceland, removing a significant regulatory hurdle. This clears the path for several biosimilar product approvals, including AVT05, AVT06, and AVT16, with decisions expected in late 2026 and early 2027. The upgrade reflects improved investor sentiment as the company addresses previous concerns regarding financial flexibility and regulatory uncertainties.